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Abstract
Background: Natriuresis with polyuria is common after aneurysmal subarachnoid hemorrhage (aSAH). Previous
studies have shown an increased risk of symptomatic cerebral vasospasm or delayed cerebral ischemia (DCI) in
patients with hyponatremia and/or the cerebral salt wasting syndrome (CSW). However, natriuresis may occur in the
absence of hyponatremia or hypovolemia and it is not known whether the increase in DCI in patients with CSW is
secondary to a concomitant hypovolemia or because the physiology that predisposes to natriuretic peptide release
also predisposes to cerebral vasospasm. Therefore, we investigated whether polyuria per se was associated with
vasospasm and whether a temporal relationship existed.
Methods: A retrospective review of patients with aSAH was performed. Exclusion criteria were admission more than
48 h after aneurysmal rupture, death within 5 days, and the development of diabetes insipidus or acute renal failure.
Polyuria was defined as >6 liters of urine in a 24 h period. Vasospasm was defined as a mean velocity > 120 m/s on
Transcranial Doppler Ultrasonography (TCDs) or by evidence of vasospasm on computerized tomography (CT) or
catheter angiography. Multivariable logistic regression was performed to assess the relationship between polyuria and
vasospasm.
Results: 95 patients were included in the study. 51 had cerebral vasospasm and 63 met the definition of polyuria.
Patients with polyuria were significantly more likely to have vasospasm (OR 4.301, 95 % CI 1.378–13.419) in multivariate
analysis. Polyuria was more common in younger patients (52 vs 68, p <.001) but did not impact mortality after
controlling for age and disease severity. The timing of the development of polyuria was clustered around the diagnosis
of vasospasm and patients with polyuria developed vasospasm faster than those without polyuria.
Conclusions: Polyuria is common after aSAH and is significantly associated with cerebral vasospasm. The development
of polyuria may be temporally related to the development of vasospasm. An increase in urine volume may be a useful
clinical predictor of patients at risk for vasospasm.
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Background
Abnormalities of sodium and water excretion are fre-
quently encountered after aneurysmal subarachnoid
hemorrhage (aSAH) and include the cerebral salt wast-
ing syndrome (CSW) and the syndrome of inappropriate
antidiuretic hormone secretion (SIADH) [1, 2]. Natri-
uresis with polyuria is a common finding in aSAH and
can contribute to hyponatremia [3]. Polyuria can also
predispose to hypovolemia if urine losses are not re-
placed in a timely fashion. Even with attempts to replace
urine losses, severe hypovolemia occurs in over half of
aSAH patients [4]. Delayed cerebral ischemia (DCI) with
or without cerebral infarction occurs in about 30 % of
patients with aSAH and is strongly linked to cerebral
vasospasm [5, 6]. Both the cerebral salt wasting syn-
drome and hyponatremia are associated with cerebral
vasospasm [7]. In two studies, the onset of hyponatremia
preceded the onset of cerebral vasospasm suggesting natri-
uresis may be a predictor of cerebral vasospasm [8, 9].
However, as hypovolemia in the setting of cerebral vaso-
spasm can increase the risk of cerebral infarction, it is not
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known if CSW is an independent phenomenon or whether
the concomitant hypovolemia explains the association [10].
Additionally, as current management of aSAH involves ag-
gressive fluid therapy to maintain euvolemia and sodium
replacement to maintain serum sodium levels, natriuresis
often leads to polyuria without hyponatremia or hypovol-
emia. Anecdotally, clinicians involved in the treatment of
aSAH have noted that an acute increase in urine output is
a harbinger of cerebral vasospasm, irrespective of volume
status. However, no studies have specifically examined the
chronology of polyuria development and cerebral vaso-
spasm risk.
The pathophysiology of polyuria after aSAH is not
fully understood, but may be related to an increase in
natriuretic peptides secondary to hypothalamic injury
[11–13]. Importantly, it has been assumed that polyuria,
when seen, leads to hyponatremia and hypovolemia, and
these factors subsequently increases the risk of DCI and
stroke. However, another explanation is that the CNS
changes that lead to natriuresis after aSAH also lead to
cerebral vasospasm. Thus, polyuria is related to the fun-
damental etiology of vasospasm and not simply a conse-
quence of fluid replacement. In that case, polyuria may
be able to identify patients at risk for vasospasm devel-
opment independently of changes in volume status and
hyponatremia. Given that urine output is a continuously
measured, noninvasive parameter, the occurrence of
polyuria may be useful for the early recognition of pa-
tients at high risk for cerebral vasospasm. We investi-
gated whether the onset of polyuria is temporally
associated with vasospasm.
Methods
We performed a retrospective chart review of all pa-
tients admitted with aSAH to our institution between
January 2012 and December 2013. The study was ap-
proved by the Hartford Hospital Institutional Review
Board (IRB). Patients were included if they had an
aneurysmal subarachnoid hemorrhage and were admit-
ted within 48 h of aneurysmal rupture (i.e. onset of
symptoms). In order to avoid the situation where pa-
tients develop polyuria, but die before the onset of vaso-
spasm, patients were excluded if they died within 5 days
of admission. Patients were also excluded if they re-
ceived mannitol after the first 24 h of admission or had
a history of or developed diabetes insipidus as these both
are independent causes of polyuria. Finally, patients were
also excluded if they developed a significant acute kidney
injury (AKI) during their hospital course as this could
mask the development of polyuria due to decreased
glomerular filtration rate. We defined AKI as a 2-fold in-
crease in serum creatinine as per both the RIFLE criteria
and stage 2 in the Kidney Disease Improving Global
Outcomes (KDIGO) grading system [14, 15].
Patients with aSAH were treated according to the
current management guidelines including early aneurysm
securing procedures, enteral nimodipine, and maintenance
of a euvolemic state. All patients had frequent measure-
ment of their intake and output and a negative fluid bal-
ance was avoided by intravenous fluid boluses and titration
of intravenous fluid maintenance rates unless symptoms of
hypervolemia indicated otherwise as per the treating the
team. Central venous pressures as well as pulse contour
analysis were utilized to ensure euvolemia if clinically indi-
cated. Patients were regularly evaluated for DCI and cere-
bral vasospasm by frequent neurologic evaluation and
Transcranial Doppler Ultrasonography (TCD). TCDs were
performed at baseline (by post-bleed day 2) and then every
1–2 days (as indicated) until at least day 10. Patients sus-
pected of having DCI or cerebral vasospasm were evalu-
ated by computerized tomography (CT) or catheter
angiography, and if present underwent hemodynamic
augmentation therapy. Patients not responding to med-
ical therapy underwent endovascular therapy including
intra-arterial calcium channel blockers and balloon
angioplasty.
Data were obtained from an IRB approved patient regis-
try as well as the patients’ electronic medical records. 24 h
urine output was obtained from the nursing flow sheets.
Polyuria was defined as urine output >6 liters in a day.
Cerebral vasospasm was defined on TCDs as a mean vel-
ocity >120 m/s plus a Lindegaard ratio >3 and on angiog-
raphy or CT angiography based on the attending
neuroradiologist’s interpretation. For consistency, any
documentation of mild, moderate, or severe vaso-
spasm was interpreted as positive for vasospasm how-
ever, terminology such as “minimal narrowing” was
not. The onset day for cerebral vasospasm was the
first day any test was consistent with cerebral vaso-
spasm as defined above. Urine output was obtained
between days 2 and 10 of admission. However, if cere-
bral vasospasm was diagnosed on or after day 10,
urine outputs were recorded up to 24 h after the day
of vasospasm onset. The onset of hyponatremia was
also defined as the first day the serum sodium was
below 135 meq/L excluding days 1 or 2 of admission.
As the main objective of this study was to identify a
temporal relationship with cerebral vasospasm, we ex-
cluded sodium or urine outputs on the first day of ad-
mission to eliminate pre-admission factors or factors
related to early resuscitation efforts, surgical proce-
dures or osmotic agents.
Analysis
The polyuria group and non-polyuria groups were com-
pared on demographics, comorbidities, and outcome.
Then patients with vasospasm were compared to those
without vasospasm by demographics, comorbidities, and
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outcome. Fisher score, Hunt Hess, and Glasgow Coma
Scale (GCS) scores were dichotomized into mild and
moderate/severe [16–18]. Many of the measures were
categorical and dichotomized and were compared using
Chi-square test. Continuous variables meeting assump-
tions of normality were analyzed using t-tests for inde-
pendent groups. Wilcoxon Ranked Sum tests were
substituted for ordinal variables (such as modified Ran-
kin score) or any continuous variables not meeting the
normality assumptions. All univariate tests were con-
ducted two sided. Multivariable logistic regression was
conducted for the prediction of vasospasm with polyuria
as the key predictor of interest. Other predictors used
included established risk factors for cerebral vasospasm
such as Hunt Hess, GCS, and Fisher score as well as any
other factors that showed a significant or near significant
relationship to vasospasm or polyuria [19–21]. Statistical
significance was defined as p <.05. Time to development
of vasospasm was compared between those who devel-
oped polyuria prior to vasospasm (n = 42) and those who
did not have polyuria (n = 32) using a log-rank test.
Results
107 patients with aneurysmal subarachnoid hemorrhage
meeting inclusion criteria were identified. 10 patients
were excluded secondary to death within 5 days of ad-
mission and 2 patients were excluded due to acute renal
failure. Ninety five patients were included in the study.
The mean age was 57.2 (range 24–91). 54 % (n = 51) of
patients had cerebral vasospasm evident on at least one
modality. More than half of these patients (57 %) were
diagnosed between days 4 and 6 (see Fig. 1). Vasospasm
was detected on TCDs only in 13 patients, CTA only in
19, angio only in 1 patient, and on TCD and CT or cath-
eter angiography in 18 patients. Vasospasm was associ-
ated with low GCS, high Fisher score, high Hunt Hess
score and the need for EVD placement (see Table 1).
Average daily urine output for the cohort is shown in
Fig. 1. 66 % (n = 63) of patients had polyuria as defined
by a 24 h urine output exceeding 6 liters on any day be-
tween days 2 and 10 of admission. These patients were
significantly more likely to develop cerebral vasospasm
in univariate analysis (p <0.01). Polyuria was significantly
associated with younger age with a mean age of 52 in
patients with polyuria vs an age of 66 in patients without
polyuria (p <.001) (see Table 2). Polyuria was also associ-
ated with the use of hypertonic saline (p = .016) which
was given to 27 of the 95 patients, 23 of whom devel-
oped polyuria. In multivariate analysis, after correcting
for age, Hunt Hess Score, Fisher Grade, the use of
hypertonic saline, and the need for ventriculostomy, pa-
tients with polyuria were 4 times more likely to develop
cerebral vasospasm (OR 4.939, 95 % CI 1.511–16.142).
Polyuria was not significantly associated with any other
factor including Hunt Hess score, admission GCS, Fisher
score, aneurysm location, sex, aneurysm securing pro-
cedure, or requirement for a ventriculostomy. There
were no differences in mortality between those with
polyuria and those without polyuria. 36 % (n = 34) of pa-
tients developed hyponatremia between days 3 and 10.
The association between vasospasm and hyponatremia
did not reach statistical significance.
In all 95 patients, the onset of polyuria occurred earl-
ier than documented cerebral vasospasm (see Fig. 1). In
Fig. 1 Vasospasm onset, polyuria onset, and average urine output by post-bleed day
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the 42 patients with polyuria and cerebral vasospasm,
vasospasm detection was clustered around the time of
polyuria onset (see Fig. 2). There were 43 patients who
developed vasospasm after the onset of polyuria or in
the absence of polyuria. Time-to-event analysis demon-
strated that patients with polyuria developed vasospasm
at a faster rate than those without polyuria (p = .0002,
see Fig. 3).
Discussion
In this study, we show that polyuria is common after
aSAH and it is significantly associated with cerebral
vasospasm. Polyuria tends to occur slightly earlier than
cerebral vasospasm and the onset of vasospasm is clus-
tered around the onset of polyuria. However, polyuria
did not impact mortality after controlling for age and in-
dicators of disease severity.
The incidence of vasospasm in this cohort is similar to
prior studies [6, 22]. The incidence of polyuria was also
high and this has not been previously reported. The ma-
jority of patients (66 %) developed polyuria on one spe-
cific day (excluding day 1) after aSAH. While we defined
polyuria as a 24 h urine output above 6 liters, outside of
the neurological intensive care unit polyuria has been
relatively arbitrarily defined as a urine volume greater
than 3 L within a 24 h period [23]. Using that definition
would have been prodigiously liberal in our cohort and
would have included 100 % of patients. Patients with
aSAH are frequently maintained on intravenous fluids
often in excess of 100 cc per hour. Given the additional
enteral or oral intake, total fluid intake is rarely below 3
liters such that a urine output below 3 liters in the
NICU is the exception rather than norm. Therefore, our
definition of polyuria was more restrictive. However, our
intention was not to show that a specific urine volume
was associated with cerebral vasospasm, but rather to
demonstrate the concept that an increase in or excessive
volume of urine over baseline in any individual patient is
a predictor of cerebral vasospasm. Based on our findings
polyuria can serve as an easily obtainable clinical pre-
dictive factor to identify patients at risk for development
of vasospasm.
Our study did not distinguish whether polyuria and
vasospasm are independent phenomena that have similar
etiologies or whether the onset of vasospasm contributes
to polyuria or vice versa. The pathophysiology of exces-
sive natriuresis and polyuria after aSAH is not com-
pletely understood however numerous studies have
demonstrated an increase in natriuretic peptides includ-
ing atrial natriuretic peptide (ANP) and brain natriuretic
peptide (BNP) [12, 13, 24, 25]. Other less known pep-
tides have been identified such as c-type natriuretic pep-
tide and dendroaspis peptide [25, 26]. Hypothalamic
dysfunction may be related to the severity of the SAH,
both clinically and radiographically and could contribute
to changes in the amount of these peptides released after
SAH. A previous study found a higher incidence of
hyponatremia with anterior communicating artery aneu-
rysms and the putative mechanism was an increased in-
cidence of hypothalamic dysfunction [27, 28]. We did
not find an association between aneurysm location and
the incidence of polyuria in this study. Regardless of the
exact cause, the excessive secretion of natriuretic pep-
tides could result in increased urinary sodium and vol-
ume loss leading to the clinical syndrome of cerebral salt
wasting. However, there is considerable controversy re-
garding this pathophysiology. For example, the increase
in natriuretic peptides may be a result of an associated
cardiac injury which occurs in about 20 % of aSAH pa-
tients and is associated with vasospasm and DCI [29].
Importantly the association between polyuria and vaso-
spasm held after controlling for well accepted measures
of severity such as Hunt and Hess score, admission GCS
and Fisher score in a multivariable model.
CSW is usually considered in the differential diagnosis
of hyponatremia in aSAH patients, and is distinguished
from SIADH by a clinical examination consistent with
hypovolemia [30, 31]. However, as hypovolemia in aSAH
patients is a known risk factor for cerebral infarction, ag-
gressive measures are employed to prevent hypovolemia.
Unlike SIADH in which isotonic fluids often exacerbate








Age, median ± SD 57 54 ± 10 61 ± 17 .020
Female 71.5 78.4 63.6 .171
GCS1 ≤ 13 38.9 49.0 27.2 .036
Fisher ≥ 3 75.8 86.3 63.6 .016
HH2 ≥ 3 51.6 62.7 38.6 .024
EVD3 70.5 84.3 54.5 .003
Polyuria 66.3 82.4 47.7 <.001
Glasgow coma score1 Hunt Hess2 External ventricular drain3. All values
expressed as a percent unless otherwise indicated. Bold indicates a p value of
less than 0.05 which is considered significant
Table 2 Baseline characteristics for patients with polyuria vs
those without polyuria
Polyuria (n=63) No polyuria (n=32) P value
Age, mean ± SD 52 ± 11 68 ± 14 <.001
Female 69.8 75.0 .639
Fisher ≥ 3 77.7 71.9 .614
HH1 ≥ 3 55.5 43.8 .288
EVD2 71.4 68.8 .815
Hunt Hess1 External ventricular drain2. All values expressed as a percent unless
otherwise indicated. Bold value indicates p value of less than 0.05 which is
considered significant
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hypoanatremia, in CSW, replacement of renal losses
with isotonic fluids may mitigate hyponatremia such that
the only manifestation of this process is polyuria. Clini-
cians who frequently treat patients with aSAH are well-
aware of sudden rises in urine output and anecdotally
have associated this with cerebral vasospasm. While
prior studies temporally linked hyponatremia with the
onset of cerebral vasospasm, no study has tried to tem-
porally link polyuria to cerebral vasospasm [8, 9]. Clinic-
ally, polyuria per se may be more useful than
hyponatremia given that urine output is generally mea-
sured hourly in aSAH patients while sodium is usually
measured daily. An increase in urine output may occur
at any time during the day and may alert clinicians to
the possibility of concomitant cerebral vasospasm. Fur-
thermore, most centers try to avoid a negative fluid bal-
ance by titrating maintenance fluid rates in order to
avoid hypovolemia. Therefore, making a diagnosis of
cerebral salt wasting has become challenging for several
reasons. First, hyponatremia is mitigated by the
Fig. 2 Vasospasm onset clusters around polyuria onset. Number of patients diagnosed with vasospasm in relationship to the day of polyuria
onset. Day 0 is the day of polyuria onset
Fig. 3 Kaplan-Meier Plot of time to vasospasm comparing the 42 patients with polyuria (excluding the 21 patients who developed vasospasm
prior to developing polyuria) on the dashed line to the 32 patients without polyuria on the solid line
Brown et al. BMC Neurology  (2015) 15:201 Page 5 of 7
avoidance of a negative fluid balance and aggressive ad-
ministration of saline. Second, even in patients who do
develop hyponatremia, distinguishing CSW from SIADH
is difficult given that the main distinguishing feature is
volume status. Finally, even if attempts to avoid hypovol-
emia fail, as studies using pulse dye densitometry have
shown, the bedside determination of volume status is
often inaccurate [4, 32]. For these reasons, we believe
that linking CSW to cerebral vasospasm is less clinically
relevant than linking urine volume to vasospasm.
Our study is limited by its retrospective design. As
stated above, it was not possible to completely rule out
the possibility that some patients’ polyuria was a result
of iatrogenic effects such as excessive fluid administra-
tion. While we excluded patients who received mannitol,
we did not exclude patients who received hypertonic sa-
line which could still have a mild diuretic effect although
the relationship of polyuria to vasospasm persisted after
controlling for this in multivariate analysis. Addition-
ally, while urine output is a continuous parameter, the
onset of cerebral vasospasm was limited to the timing of
investigative tests. TCDs may not be performed daily in
low risk patients without clinical changes and CTAs and
conventional angiograms are often ordered only if vaso-
spasm is suspected. Therefore, it is possible that vaso-
spasm was missed in some patients or that the actual
day of onset was earlier than recorded. It is also import-
ant to note that we chose to link polyuria to cerebral
vasospasm rather than to delayed cerebral ischemia
(DCI) which may be the more clinically relevant out-
come than cerebral vasospasm [33]. This was not an
oversight, but was intentional given the retrospective na-
ture of this study, as linking polyuria to DCI would
make it difficult to distinguish whether polyuria was a
response to treatment. Once a patient is diagnosed with
DCI, vasopressors are initiated and patients may receive
additional fluid boluses, both of which may increase
urine output. However, asymptomatic cerebral vaso-
spasm is generally not treated with vasopressors or a
change in fluid strategy. While our results may still be
confounded by the patients who did develop DCI, by
linking polyuria to mild vasospasm, which usually is not
yet associated with ischemia, we believe the onset of
polyuria coinciding with the onset of cerebral vasospasm
was largely independent of iatrogenic issues. The retro-
spective design also made it difficult to determine who
and when DCI was diagnosed as this is mainly an inter-
pretation of chart notes whereas vasospasm was defined
objectively by TCD changes and radiological findings.
This study was also limited to the association with daily
urine outputs. Future studies will examine hourly out-
puts and determine if precipitous changes in urine out-
put are predictive of cerebral vasospasm. Future studies
will also investigate whether the severity of vasospasm is
associated with the incidence and degree of polyuria. Fi-
nally, while we did not detect an association of polyuria
with mortality, clinical or radiological grade, or
aneurysm location, a larger study may have detected an
association as this initial study has limited power, despite
being the largest to date on this topic.
Conclusion
In summary, we have shown that polyuria is significantly
associated with cerebral vasospasm and that polyuria on-
set is clustered with the onset of cerebral vasospasm.
This may be useful in determining which patients are at
high risk of developing vasospasm and developing future
recommendations for the monitoring and disposition of
these patients. A prospective study is necessary to fur-
ther evaluate this association.
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